SWM
MCRB icon

Spire Wealth Management’s Seres Therapeutics MCRB Stock Holding History

Spire Wealth Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8
Closed -$1K – 2732
2021
Q4 		$1K Buy
+8
New +$1.27K ﹤0.01% 2879
2021
Q2 		– Sell
-8
Closed -$3K – 2813
2021
Q1 		$3K Buy
+8
New +$3.68K ﹤0.01% 2759

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Spire Wealth Management's MCRB Position: Q1 2022 in Review

Spire Wealth Management sold out of Seres Therapeutics (MCRB) in Q1 2022, closing a stake of 8 shares — an estimated $1K sold.

Spire Wealth Management first reported a position in MCRB in Q1 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 131 funds tracked by Wall St. Rank hold MCRB as of Q1 2022.

  • Spire Wealth Management reported no remaining Seres Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 8 Seres Therapeutics shares in Q1 2022, an estimated $1K.
  • Spire Wealth Management first reported a position in Seres Therapeutics in Q1 2021 and held it in 2 quarters.
  • Spire Wealth Management's Seres Therapeutics position peaked at $3K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.